Secreted Klotho and chronic kidney disease

Ming C Hu, Makoto Kuro-o, Orson W Moe

Research output: Chapter in Book/Report/Conference proceedingChapter

73 Citations (Scopus)

Abstract

Soluble Klotho (sKl) in the circulation can be generated directly by alterative splicing of the Klotho transcript or the extracellular domain of membrane Klotho can be released from membrane-anchored Klotho on the cell surface. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23), sKl, acts as hormonal factor and plays important roles in anti-aging, anti-oxidation, modulation of ion transport, and Wnt signaling. Emerging evidence reveals that Klotho deficiency is an early biomarker for chronic kidney diseases as well as a pathogenic factor. Klotho deficiency is associated with progression and chronic complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. In multiple experimental models, replacement of sKl, or manipulated up-regulation of endogenous Klotho protect the kidney from renal insults, preserve kidney function, and suppress renal fibrosis, in chronic kidney disease. Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Pages126-157
Number of pages32
Volume728
DOIs
StatePublished - 2012

Publication series

NameAdvances in Experimental Medicine and Biology
Volume728
ISSN (Print)00652598

Fingerprint

Chronic Renal Insufficiency
Kidney
Biomarkers
Membranes
Vascular Calcification
Secondary Hyperparathyroidism
Ion Transport
Cardiomegaly
Fibrosis
Theoretical Models
Up-Regulation
Aging of materials
Modulation
Ions
Oxidation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hu, M. C., Kuro-o, M., & Moe, O. W. (2012). Secreted Klotho and chronic kidney disease. In Advances in Experimental Medicine and Biology (Vol. 728, pp. 126-157). (Advances in Experimental Medicine and Biology; Vol. 728). https://doi.org/10.1007/978-1-4614-0887-1_9

Secreted Klotho and chronic kidney disease. / Hu, Ming C; Kuro-o, Makoto; Moe, Orson W.

Advances in Experimental Medicine and Biology. Vol. 728 2012. p. 126-157 (Advances in Experimental Medicine and Biology; Vol. 728).

Research output: Chapter in Book/Report/Conference proceedingChapter

Hu, MC, Kuro-o, M & Moe, OW 2012, Secreted Klotho and chronic kidney disease. in Advances in Experimental Medicine and Biology. vol. 728, Advances in Experimental Medicine and Biology, vol. 728, pp. 126-157. https://doi.org/10.1007/978-1-4614-0887-1_9
Hu MC, Kuro-o M, Moe OW. Secreted Klotho and chronic kidney disease. In Advances in Experimental Medicine and Biology. Vol. 728. 2012. p. 126-157. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-0887-1_9
Hu, Ming C ; Kuro-o, Makoto ; Moe, Orson W. / Secreted Klotho and chronic kidney disease. Advances in Experimental Medicine and Biology. Vol. 728 2012. pp. 126-157 (Advances in Experimental Medicine and Biology).
@inbook{bd347ea595dd4d2997c8b55fb21cb775,
title = "Secreted Klotho and chronic kidney disease",
abstract = "Soluble Klotho (sKl) in the circulation can be generated directly by alterative splicing of the Klotho transcript or the extracellular domain of membrane Klotho can be released from membrane-anchored Klotho on the cell surface. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23), sKl, acts as hormonal factor and plays important roles in anti-aging, anti-oxidation, modulation of ion transport, and Wnt signaling. Emerging evidence reveals that Klotho deficiency is an early biomarker for chronic kidney diseases as well as a pathogenic factor. Klotho deficiency is associated with progression and chronic complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. In multiple experimental models, replacement of sKl, or manipulated up-regulation of endogenous Klotho protect the kidney from renal insults, preserve kidney function, and suppress renal fibrosis, in chronic kidney disease. Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.",
author = "Hu, {Ming C} and Makoto Kuro-o and Moe, {Orson W}",
year = "2012",
doi = "10.1007/978-1-4614-0887-1_9",
language = "English (US)",
isbn = "9781461408864",
volume = "728",
series = "Advances in Experimental Medicine and Biology",
pages = "126--157",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Secreted Klotho and chronic kidney disease

AU - Hu, Ming C

AU - Kuro-o, Makoto

AU - Moe, Orson W

PY - 2012

Y1 - 2012

N2 - Soluble Klotho (sKl) in the circulation can be generated directly by alterative splicing of the Klotho transcript or the extracellular domain of membrane Klotho can be released from membrane-anchored Klotho on the cell surface. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23), sKl, acts as hormonal factor and plays important roles in anti-aging, anti-oxidation, modulation of ion transport, and Wnt signaling. Emerging evidence reveals that Klotho deficiency is an early biomarker for chronic kidney diseases as well as a pathogenic factor. Klotho deficiency is associated with progression and chronic complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. In multiple experimental models, replacement of sKl, or manipulated up-regulation of endogenous Klotho protect the kidney from renal insults, preserve kidney function, and suppress renal fibrosis, in chronic kidney disease. Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.

AB - Soluble Klotho (sKl) in the circulation can be generated directly by alterative splicing of the Klotho transcript or the extracellular domain of membrane Klotho can be released from membrane-anchored Klotho on the cell surface. Unlike membrane Klotho which functions as a coreceptor for fibroblast growth factor-23 (FGF23), sKl, acts as hormonal factor and plays important roles in anti-aging, anti-oxidation, modulation of ion transport, and Wnt signaling. Emerging evidence reveals that Klotho deficiency is an early biomarker for chronic kidney diseases as well as a pathogenic factor. Klotho deficiency is associated with progression and chronic complications in chronic kidney disease including vascular calcification, cardiac hypertrophy, and secondary hyperparathyroidism. In multiple experimental models, replacement of sKl, or manipulated up-regulation of endogenous Klotho protect the kidney from renal insults, preserve kidney function, and suppress renal fibrosis, in chronic kidney disease. Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.

UR - http://www.scopus.com/inward/record.url?scp=84859522038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859522038&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-0887-1_9

DO - 10.1007/978-1-4614-0887-1_9

M3 - Chapter

C2 - 22396167

AN - SCOPUS:84859522038

SN - 9781461408864

VL - 728

T3 - Advances in Experimental Medicine and Biology

SP - 126

EP - 157

BT - Advances in Experimental Medicine and Biology

ER -